JAMA Neurology
LightNews LightNews
banner
jamaneurology.com
JAMA Neurology
@jamaneurology.com
140 followers 94 following 130 posts
JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

🌐 JAMANeurology.com
Posts Replies Media Videos
jamaneurology.com
Among patients <70 years with acute #BasilarArteryOcclusion, endovascular thrombectomy doubled the rate of ambulatory and self-care capable outcomes at 3 years vs medical treatment.

ja.ma/4jnUUej
Horizontal bar graph titled 'Distribution of Functional Outcomes at 3 Years'. Two groups, Thrombectomy and Control, are compared using mRS scores (0 to 6) with percentages of patients on the x-axis. Thrombectomy group shows better outcomes.
December 31, 2025 at 2:00 PM
jamaneurology.com
Among patients <70 years with acute #BasilarArteryOcclusion, endovascular thrombectomy doubled the rate of ambulatory and self-care capable outcomes at 3 years vs medical treatment.

ja.ma/4jdqGKQ
Figure 1 shows the distribution of functional outcomes at 3 years in the intent-to-treat population for thrombectomy (n=203) and control (n=104) groups, based on mRS score represented in percentage of patients.
December 29, 2025 at 4:30 PM
jamaneurology.com
In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy. ja.ma/4atDFWx
JAMA Neurology study on antithrombotics for stroke/atrial fibrillation. 226 men, 90 women studied across 41 Japanese hospitals. Intervention: 316 patients randomized, comparing anticoagulant/antiplatelet vs. monotherapy. No net benefit found with combined therapy.
December 27, 2025 at 12:00 PM
jamaneurology.com
Earlier initiation of tofersen slowed clinical decline, sustained biomarker improvement, and extended survival for SOD1-related #ALS, with no new long-term safety concerns.

ja.ma/3MSbSVV
Figure 1. Four plots showing change in outcomes from baseline to week 148 for Plasma NfL, ALSFRS-R, SVC, and HHD megascore. Each plot compares Placebo/delayed-start tofersen and Early-start tofersen over time.
December 26, 2025 at 3:00 PM
jamaneurology.com
The numbers are in.

This year's most popular JAMA Network content spans a range of topics, from #fluoride to #Parkinson disease to #GLP-1s. What was your favorite article in 2025, and did other readers agree?

🔗 ja.ma/4saoMP5
A collage of medical graphs and diagrams. Text includes "Life-years saved," "JAMA Network 2025," and information on postnasal drip symptoms and treatments. Charts show data related to cannabis use, age, and transplant types.
December 25, 2025 at 12:00 PM
jamaneurology.com
Earlier initiation of tofersen slowed clinical decline, sustained biomarker improvement, and extended survival for SOD1-related #ALS, with no new long-term safety concerns.

ja.ma/4qqOZaF
Figure 1. Four plots showing change in outcomes from baseline to week 148 for Plasma NfL, ALSFRS-R, SVC, and HHD megascore. Each plot compares Placebo/delayed-start tofersen and Early-start tofersen over time.
December 24, 2025 at 4:00 PM
jamaneurology.com
A 62-year-old man presented with progressive limb weakness and involuntary movements. Take the Clinical Challenge.

What is your diagnosis?

ja.ma/3MP4oTI
Axial T1 and T2-weighted MRI of thighs showing hyperintense lesions (arrowheads) within the bilateral thigh muscles, predominantly affecting the posterior compartment. The MRI scans show cross-sectional views of the upper legs.
December 24, 2025 at 12:00 PM
jamaneurology.com
The numbers are in.

The numbers are in. This year's most popular JAMA Network content spans a range of topics, from #fluoride to #Parkinson disease to #GLP-1s. What was your favorite article in 2025 -- and did other readers agree?

🔗 ja.ma/4jk4HlG
A collage of medical graphs and diagrams. Text includes "Life-years saved," "JAMA Network 2025," and information on postnasal drip symptoms and treatments. Charts show data related to cannabis use, age, and transplant types.
December 23, 2025 at 4:30 PM
jamaneurology.com
This case report describes a man presenting with amnestic seizure events manifesting with a wind swirl pattern on density spectral array, resulting in a diagnosis of anti–γ-aminobutyric acid B (GABAB) receptor antibody–associated encephalitis.

ja.ma/4qmchyr
Figure 2. Repeat Magnetic Resonance Imaging shows hyperintensity in the bilateral mesial temporal regions. The image has an arrow head on the left of "R".The finding is also evident on T1-weighted.
December 23, 2025 at 3:00 PM
jamaneurology.com
Case report: a 58-year-old patient presenting with seizures and undergoing craniotomy, during which a live parasitic worm was discovered.

ja.ma/3LgK2Cj
Figure 2, Migration of Lesion, shows two preoperative CT scans of a brain. Image A is the "First of 2 preoperative CT scans" and Image B notes "Migration of the lesion noted on second scan 2 d later".
December 23, 2025 at 12:00 PM
jamaneurology.com
Earlier initiation of tofersen slowed clinical decline, sustained biomarker improvement, and extended survival for SOD1-related #ALS, with no new long-term safety concerns.

ja.ma/3Y7vY0M
Figure 1. Four plots showing change in outcomes from baseline to week 148 for Plasma NfL, ALSFRS-R, SVC, and HHD megascore. Each plot compares Placebo/delayed-start tofersen and Early-start tofersen over time.
December 22, 2025 at 4:30 PM
jamaneurology.com
Case report: A 73-year-old woman presented with dysarthria and right-sided hemiparesis (NIH-Stroke Scale score of 9). ja.ma/3KWVOBO
Angiographic view of cerebral arteries. The first image shows occlusion of the left middle cerebral artery. The second shows partial recanalization with remaining stenosis, indicated by a yellow triangle. "Figure 1" is written on top.
December 22, 2025 at 12:00 PM
jamaneurology.com
The annual rate of first intracranial hemorrhage from unruptured brain AVMs was 1.4% in a multinational cohort, lower than commonly cited estimates. ja.ma/3MLJ3us
Kaplan-Meier survival curve shows time to first hemorrhage after brain arteriovenous malformation diagnosis. X-axis: Time since diagnosis (years). Y-axis: Probability of hemorrhage. The curve gradually increases over time, with shaded confidence intervals.
December 21, 2025 at 12:00 PM
jamaneurology.com
From @jama.com: Valacyclovir was associated with greater cognitive decline and did not improve disease markers in patients with symptomatic #AlzheimerDisease and HSV seropositivity.

ja.ma/3YB0S1E
JAMA infographic: study on valacyclovir for Alzheimer's. Question: Can valacyclovir provide benefit? Conclusion: Not efficacious. Population: 66 women, 54 men, mean age 71.4. Intervention: 120 patients randomized to valacyclovir or placebo. Findings: Valacyclovir worsened cognition vs. placebo.
December 20, 2025 at 3:00 PM
jamaneurology.com
General anesthesia improved 90-day disability outcomes and increased the rate of successful reperfusion compared with moderate sedation in patients undergoing endovascular thrombectomy for acute ischemic stroke.

ja.ma/44CZBed
Infographic titled "JAMA Neurology RCT: Sedation vs General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke" presents population(133 Men, 125 women), intervention, findings, settings/locations, primary outcome.
December 20, 2025 at 12:00 PM
jamaneurology.com
Among patients with focal treatment-resistant epilepsy, seizure frequency often decreases over time regardless of changes in medication or neuromodulation device use. ja.ma/4qiNbAy
Figure shows seizure trends over time. Graph A: Monthly seizure count by cohort for >0 to <=12, >12 to <=24 and >24. Graph B: Trend lines by cohort over 12 months for cohort 1, cohort 2, and cohort 3.
December 19, 2025 at 12:00 PM
jamaneurology.com
Lower posttreatment amyloid plaque after donanemab was correlated with slower clinical decline and reduced AD-related plasma biomarkers in TRAILBLAZER-ALZ 2. ja.ma/4p4UXgr
Two scatter plots show correlation of posttreatment amyloid value with 76-week changes in clinical progression. Plot A: change in iADRS score vs amyloid value. Plot B: change in CDR-SB score vs amyloid value. Both plots have a downward trending line.
December 18, 2025 at 12:00 PM
jamaneurology.com
A secondary analysis of the TEMPO-2 RCT found no significant improvement in outcomes for minor ischemic stroke patients treated with intravenous tenecteplase, regardless of the presence of disabling deficits. ja.ma/44x13yE
JAMA Neurology: RCT, Thrombolysis With Tenecteplase for Minor Disabling Stroke shows population (515 men, 369 women), intervention(886 patients), usual care, findings, settings/locations(48 hospitals globally), primary outcome.
December 17, 2025 at 12:00 PM
jamaneurology.com
AI-driven TPNS device improved daily activity scores for #EssentialTremor at 90 days versus sham in a multicenter RCT. Device may offer a new noninvasive option for ET; mild skin irritation was most common adverse event.

ja.ma/3KO6Mte
JAMA Neurology infographic on Transcutaneous Peripheral Nerve Stimulation for Essential Tremor. The study includes 63 men and 62 women with an average age of 64.9 years. Findings show a 6.9-point mADL score decrease in the TPNS group vs. 2.7 in the sham group.
December 16, 2025 at 12:03 PM
jamaneurology.com
Editorial: Plasma tau biomarkers such as p-tau217 are robust predictors of #AlzheimerDisease pathology, but their use as interchangeable substitutes for tau PET imaging may be limited, especially in the context of disease stage and anti-amyloid treatment. ja.ma/48Utzf1
An editorial titled "A Test of the Alzheimer Disease Framework—Did It Pass?" by Ronald C. Petersen, PhD, MD, and Henrik Zetterberg, MD, PhD, discusses the evolution of Alzheimer's criteria and the use of biomarkers like p-tau217.
December 15, 2025 at 5:00 PM
jamaneurology.com
Individuals with #AlzheimerDisease showing greater clinical impairment than predicted by tau burden are more likely to have copathology, including #TDP43 and #AlphaSynuclein, and experience faster decline. ja.ma/3KLq5Du
Figure 4. Graphs show mismatch models in Penn Antiamyloid Therapy Monitoring(ATM) cohort. Graph A is classification, B is time calculation from tau positivity. Graphs C and D show change in CDR-SB score over treatment time and after 18 months.
December 15, 2025 at 4:30 PM
jamaneurology.com
In patients with ischemic stroke and concurrent nonvalvular atrial fibrillation and ASCVD, adding an antiplatelet agent to anticoagulant therapy offered no net clinical benefit over anticoagulant monotherapy. ja.ma/4pDnNpf
JAMA Neurology displays RCT results: Optimal Antithrombotics for Ischemic Stroke, Concurrent Atrial Fibrillation, Atherosclerosis. 226 men, 90 women. 316 patients analyzed; anticoagulant therapies compared. Cumulative incidence: Combination 17.8%, Monotherapy 19.6%.
December 15, 2025 at 12:00 PM
jamaneurology.com
#Menopause was not associated with increased risk of disability progression or secondary progressive MS in women with relapse-onset MS. ja.ma/3YpVfDr
Graph titled "Figure 2. Predicted Extended Disability Status Scale (EDSS) Inflection Point Analysis". X axis is labeled as "Time since menopause, y" from -25 to 25. Y axis is labeled as "EDSS score" from 0 to 10. Data points are scattered.
December 14, 2025 at 12:00 PM
jamaneurology.com
💬 Editorial: Recent trials show intravenous thrombolysis provides no clear benefit for patients presenting to the emergency department with mild stroke (NIHSS 0–5), highlighting the need for highly individualized treatment decisions.

ja.ma/48VH8L3
Table outlining mild stroke eligibility criteria in major randomized trials of IVT. It lists inclusion and exclusion criteria, detailing randomized trials such as NINDS, ECASS, ATLANTIS, IST-3, PRISMS, ARAMIS, and TEMPO-2.
December 13, 2025 at 12:00 PM
jamaneurology.com
Editorial: Recent trials of wearable nerve stimulators for essential tremor offer limited benefit over placebo. Noninvasive therapies may expand options for ET, but more evidence is needed before these devices achieve widespread uptake. ja.ma/3MvoYs4
JAMA Neurology editorial, "Neuromodulation and Tremor Suppression in the Periphery" by Theresa A. Zesiewicz, Peter A. LeWitt, and Elan D. Louis. Published online October 20, 2025. Includes author affiliations and article information.
December 12, 2025 at 12:00 PM